Ticrynafen

CHEMBL267744 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

331.2 g/mol

LogP

4.1

Phase

4

Ticrynafen (tienilic acid) is a uricosuric diuretic and antihypertensive agent that inhibits renal tubular reabsorption of urate while also blocking sodium and chloride reabsorption. It was withdrawn from the market due to severe hepatotoxicity, including fatal hepatic necrosis associated with drug-metabolite-induced autoimmune liver injury. Its combined uricosuric and antihypertensive properties were clinically attractive, but the idiosyncratic hepatotoxic mechanism involving CYP2C9-generated reactive metabolites made it unsafe.

الوزن الجزيئي

331,2000 g/mol

LogP

4,10

TPSA

91,80 Å²

قاعدة ليبينسكي للخمسة

ناجح

Pharmacokinetics (PK)

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl

InChI

InChI=1S/C13H8Cl2O4S/c14-11-7(13(18)9-2-1-5-20-9)3-4-8(12(11)15)19-6-10(16)17/h1-5H,6H2,(H,16,17)

Molecular Formula

C13H8Cl2O4S

HBD / HBA

1 / 5

الروابط القابلة للدوران

5

الذرات الثقيلة

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

Ticrynafen (tienilic acid) is a uricosuric diuretic and antihypertensive agent that inhibits renal tubular reabsorption of urate while also blocking sodium and chloride reabsorption. It was withdrawn from the market due to severe hepatotoxicity, including fatal hepatic necrosis associated with drug-metabolite-induced autoimmune liver injury. Its combined uricosuric and antihypertensive properties were clinically attractive, but the idiosyncratic hepatotoxic mechanism involving CYP2C9-generated reactive metabolites made it unsafe.

Yes, Ticrynafen is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL267744. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 38409. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Ticrynafen على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C13H8Cl2O4S

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.